Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a blood protein boost survival in septic shock?

NCT ID NCT07212582

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 37 times

Summary

This study tests whether giving extra human albumin—a natural blood protein—along with standard care can help people survive septic shock after surgery. Septic shock is a life-threatening condition where infection causes dangerously low blood pressure. The trial will enroll 304 adults in the surgical ICU, giving some patients albumin infusions for up to 3 days to keep their albumin levels high. The main goal is to see if more patients are alive at 28 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Faculty of Medicine, Siriraj Hospital, Mahidol University

    Bangkok, Bangkoknoi, 10700, Thailand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

human albumin (20% solution)

What this could lead to

If it works, this could point toward a simple, widely available treatment to improve survival in surgical septic shock.

What could go wrong

This is a single-center trial with 304 patients, so results may not apply everywhere. Previous studies on albumin in sepsis have had mixed results, so there is no guarantee of benefit.

Conditions

The condition(s) this trial relates to.

Critical Illness toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.